CVS

CVS Investment Thesis In 300 Words

“Davidson” submits:

Q1 hedge fund letters, conference, scoops etc

CVSHealth(CVS) is a portfolio suggestion. CVS recently closed its acquisition of Aetna, a healthcare benefits manager. Synergies are expected to extend CVS’s strong financial history. Investors have turned negative and repriced CVS below 10yr lows in Price/Sales and Price/Cash Flows. The last time CVS insiders were active buyers occurred during 2010-2012 lows.

https://investors.cvshealth.com/investors/investor-story/default.aspx

CVS Health describes the company as a health care innovation company helping people on their path to better health helping to foster healthier communities. The acquisition of Aetna, is CVS’s focus on building a new health care model that is easier to use, less expensive and putting the consumer first.

The new CVS health care model is geared to provide significant opportunities to create incremental value and accelerate growth across the enterprise. CVS envisions lower health care costs contributing to improved profitability, enhanced competitive positioning. CVS expects to generate substantial cash flow for reinvestment with a focus on driving shareholder value over the long term.

CVS’s 4Q18 Earnings presentation summarizes management’s expectations.

CVS

CVS

CVS’s Morningstar financial history reflects a strong management team and its price history reflects near term investor confusion.

CVS

CVS

CVS long-term share-price performance has pace its financial performance as investors turned more positive following results.

CVS

Recent insider buying for CVS is an unusual event and a positive investment signal.

CVS

The Investment Thesis:

CVS stands out for its long history of superb financial management. The recent acquisition of Aetna to combine a benefits manager with a direct consumer delivery of products/services is the first step of integrating healthcare delivery to lower costs and remain highly competitive in an industry seeing significant demand for lower cost. If management meets its goals, the share’s price should recover to historical trend. Shares currently priced ~$55shr with 3.7% dividend have the potential to price over $100shr in several years.


Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted & limited time offer for being a sophisticated and loyal reader.

ValueWalkPremium is a website and newsletter on the latest industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today and get our exclusive content for 40% off. This is our second biggest discount ever!!

Use coupon code VIP20 or click on the button below

Limited time offer only ENDS 4/30/2020 or after the next 40 subscribers take advantage whichever comes first – please do not share this discount with others

 

0